Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis with Biological Agents - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Therapeutic Drug Monitoring Année : 2017

Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis with Biological Agents

Résumé

Multiple sclerosis is a heterogenous disease. Although several EMA-approved disease-modifying treatments including biopharmaceuticals are available, their efficacy is limited, and a certain percentage of patients are always nonresponsive. Drug efficacy monitoring is an important tool to identify these nonresponsive patients early on. Currently, detection of antidrug antibodies and quantification of biological activity are used as methods of efficacy monitoring for interferon beta and natalizumab therapies. For natalizumab and alemtuzumab treatments, drug level quantification could be an essential component of the overall disease management. Thus, utilization and development of strategies to determine treatment response are vital aspects of multiple sclerosis management given the tremendous clinical and economic promise of this tool.
Fichier principal
Vignette du fichier
2017TDMaccepted.pdf (227.68 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

inserm-01755556 , version 1 (30-03-2018)

Identifiants

Citer

Marzia Caldano, William Raoul, Theo Rispens, Antonio Bertolotto. Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis with Biological Agents: Efficacy monitoring of biological agents in Multiple Sclerosis. Therapeutic Drug Monitoring, 2017, 39 (4), pp.350 - 355. ⟨10.1097/FTD.0000000000000393⟩. ⟨inserm-01755556⟩
96 Consultations
258 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More